Study to Optimize Keverprazan and Amoxicillin Dual Therapy for Treating Helicobacter Pylori Infection with Different Doses and Durations

What this Trial Is About

Researchers are evaluating Keverprazan-amoxicillin dual therapy to improve treatment for Helicobacter pylori HP infection, which is linked to several serious diseases. Traditional quadruple treatments can cause severe side effects, high costs, and poor compliance. Keverprazan, a new potassium acid blocker, may offer a stronger and longer-lasting acid inhibition that is not affected by genetic differences, potentially improving eradication rates and patient experience. This study aims to compare different doses and durations of Keverprazan-amoxicillin dual therapy to find the most effective approach. The trial compares three treatment regimens a 14-day course with high-dose amoxicillin 1000 mg three times daily, a 14-day course with a lower dose of amoxicillin 1000 mg twice daily, and a 10-day course with high-dose amoxicillin 1000 mg three times daily. All groups receive Keverprazan hydrochloride tablets 20 mg twice daily orally. These regimens are studied to assess their effectiveness in eradicating HP infection while monitoring side effects and treatment adherence. Participants are adults aged 18 to 75 years who have tested positive for HP infection and may have failed previous eradication attempts. They will take their assigned therapy and attend study visits for monitoring. Researchers will measure HP eradication rates six weeks after treatment, along with any adverse events and medical costs. The study includes safety monitoring and adherence checks to ensure reliable results over the treatment and follow-up periods.

Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection